HMGB1 Protein: A Therapeutic Target Inside and Outside the Cell

Advances in Protein Chemistry and Structural Biology

Volumn 107, Issue , 2017, Pages 37-76

  Ugrinova, I ^a   Pasheva, E ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Bulgaria)

Author keywords

cis Platinum; HMGB1; microRNAs; Receptors; Targeting strategies; Therapeutic target

Indexed keywords

ANTIBODY; CISPLATIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; MICRORNA; OLIGONUCLEOTIDE; RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CELLS; HUMAN; MOLECULE; PROTEIN PROCESSING; PROTEIN STRUCTURE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL NUCLEUS; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL NUCLEUS; HMGB1 PROTEIN; HUMANS; MICRORNAS;

EID: 85007439481     PISSN: 18761623     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.apcsb.2016.10.001     Document Type: Chapter

References (181)

1. Akira, S., Takeda, K., Toll-like receptor signalling. Nature Reviews. Immunology 4:7 (2004), 499–511, 10.1038/nri1391.
2. Alexandrova, E.A., Beltchev, B.G., Acetylated HMG1 protein interacts specifically with homologous DNA polymerase alpha in vitro. Biochemical and Biophysical Research Communications 154:3 (1988), 918–927.
3. Andersson, U., Harris, H.E., The role of HMGB1 in the pathogenesis of rheumatic disease. Biochimica et Biophysica Acta 1799:1–2 (2010), 141–148, 10.1016/j.bbagrm.2009.11.003.
4. Andersson, U., Tracey, K.J., HMGB1 in sepsis. Scandinavian Journal of Infectious Diseases 35:9 (2003), 577–584.
5. Andersson, U., Tracey, K.J., HMGB1 is a therapeutic target for sterile inflammation and infection. Annual Review of Immunology 29 (2011), 139–162, 10.1146/annurev-immunol-030409-101323.
6. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Zitvogel, L., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine 13:9 (2007), 1050–1059, 10.1038/nm1622.
7. Asavarut, P., Zhao, H., Gu, J., Ma, D., The role of HMGB1 in inflammation-mediated organ injury. Acta Anaesthesiologica Taiwanica 51:1 (2013), 28–33, 10.1016/j.aat.2013.03.007.
8. Assenberg, R., Webb, M., Connolly, E., Stott, K., Watson, M., Hobbs, J., Thomas, J.O., A critical role in structure-specific DNA binding for the acetylatable lysine residues in HMGB1. The Biochemical Journal 411:3 (2008), 553–561, 10.1042/BJ20071613.
9. Azzoli, C.G., Baker, S. Jr., Temin, S., Pao, W., Aliff, T., Brahmer, J., American Society of Clinical Oncology, American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. Journal of Clinical Oncology 27:36 (2009), 6251–6266, 10.1200/JCO.2009.23.5622.
10. Bangert, A., Andrassy, M., Muller, A.M., Bockstahler, M., Fischer, A., Volz, C.H., Kaya, Z., Critical role of RAGE and HMGB1 in inflammatory heart disease. Proceedings of the National Academy of Sciences of the United States of America 113:2 (2016), E155–E164, 10.1073/pnas.1522288113.
11. Bauer, E.M., Shapiro, R., Billiar, T.R., Bauer, P.M., High mobility group Box 1 inhibits human pulmonary artery endothelial cell migration via a Toll-like receptor 4- and interferon response factor 3-dependent mechanism(s). The Journal of Biological Chemistry 288:2 (2013), 1365–1373, 10.1074/jbc.M112.434142.
12. Bianchi, M.E., Beltrame, M., Paonessa, G., Specific recognition of cruciform DNA by nuclear protein HMG1. Science 243:4894 Pt. 1 (1989), 1056–1059.
13. Bianchi, M.E., Falciola, L., Ferrari, S., Lilley, D.M., The DNA binding site of HMG1 protein is composed of two similar segments (HMG boxes), both of which have counterparts in other eukaryotic regulatory proteins. EMBO Journal 11:3 (1992), 1055–1063.
14. Bonaldi, T., Langst, G., Strohner, R., Becker, P.B., Bianchi, M.E., The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding. The EMBO Journal 21:24 (2002), 6865–6873.
15. Bonaldi, T., Talamo, F., Scaffidi, P., Ferrera, D., Porto, A., Bachi, A., Bianchi, M.E., Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. The EMBO Journal 22:20 (2003), 5551–5560, 10.1093/emboj/cdg516.
16. Bonne-Andrea, C., Harper, F., Sobczak, J., De Recondo, A.M., The role of HMG1 protein in nucleosome assembly and in chromatin replication. Adv. Exp. Med. Biol. 179 (1984), 479–488.
17. Brezniceanu, M.L., Volp, K., Bosser, S., Solbach, C., Lichter, P., Joos, S., Zornig, M., HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. The FASEB Journal 17:10 (2003), 1295–1297, 10.1096/fj.02-0621fje.
18. Bucci, E.M., Valente, M., Musumeci, D., Sapio, R., Anro, V., Roviello, G.N., Moccia, M., ODN-based drugs for targeting of extracellular proteins. Nucleosides, Nucleotides & Nucleic Acids 26:8–9 (2007), 1047–1050, 10.1080/15257770701509602.
19. Bucciarelli, L.G., Wendt, T., Qu, W., Lu, Y., Lalla, E., Rong, L.L., Schmidt, A.M., RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106:22 (2002), 2827–2835.
20. Casula, M., Iyer, A.M., Spliet, W.G., Anink, J.J., Steentjes, K., Sta, M., Aronica, E., Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 179 (2011), 233–243, 10.1016/j.neuroscience.2011.02.001.
21. Cato, L., Stott, K., Watson, M., Thomas, J.O., The interaction of HMGB1 and linker histones occurs through their acidic and basic tails. Journal of Molecular Biology 384:5 (2008), 1262–1272, 10.1016/j.jmb.2008.10.001.
22. Celona, B., Weiner, A., Di Felice, F., Mancuso, F.M., Cesarini, E., Rossi, R.L., Agresti, A., Substantial histone reduction modulates genomewide nucleosomal occupancy and global transcriptional output. PLoS Biology, 9(6), 2011, e1001086, 10.1371/journal.pbio.1001086.
23. Chen, Q., Guan, X., Zuo, X., Wang, J., Yin, W., The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases. Acta Pharmaceutica Sinica B 6:3 (2016), 183–188, 10.1016/j.apsb.2016.02.004.
24. Chen, M., Liu, Y., Varley, P., Chang, Y., He, X.X., Huang, H., Tsung, A., High-mobility group box 1 promotes hepatocellular carcinoma progression through miR-21-mediated matrix metalloproteinase activity. Cancer Research 75:8 (2015), 1645–1656, 10.1158/0008-5472.CAN-14-2147.
25. Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Jinushi, M., Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nature Immunology 13:9 (2012), 832–842, 10.1038/ni.2376.
26. Choi, H.W., Tian, M., Song, F., Venereau, E., Preti, A., Park, S.W., Klessig, D.F., Aspirin's active metabolite salicylic acid targets high mobility group box 1 to modulate inflammatory responses. Molecular Medicine 21 (2015), 526–535, 10.2119/molmed.2015.00148.
27. Chorny, A., Delgado, M., Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. The American Journal of Pathology 172:5 (2008), 1297–1307, 10.2353/ajpath.2008.070969.
28. Chu, G., Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. The Journal of Biological Chemistry 269:2 (1994), 787–790.
29. Ciccarelli, R.B., Solomon, M.J., Varshavsky, A., Lippard, S.J., In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: Differential repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry 24:26 (1985), 7533–7540.
30. Conti, L., Lanzardo, S., Arigoni, M., Antonazzo, R., Radaelli, E., Cantarella, D., Cavallo, F., The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. The FASEB Journal 27:12 (2013), 4731–4744, 10.1096/fj.13-230201.
31. Das, U.N., Is multiple sclerosis a proresolution deficiency disorder?. Nutrition 28:10 (2012), 951–958, 10.1016/j.nut.2011.12.016.
32. Das, D., Scovell, W.M., The binding interaction of HMG-1 with the TATA-binding protein/TATA complex. The Journal of Biological Chemistry 276:35 (2001), 32597–32605, 10.1074/jbc.M011792200.
33. Dave, S.H., Tilstra, J.S., Matsuoka, K., Li, F., DeMarco, R.A., Beer-Stolz, D., Plevy, S.E., Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. Journal of Leukocyte Biology 86:3 (2009), 633–643, 10.1189/jlb.1008662.
34. de Silva, S., Lotta, L.T. Jr., Burris, C.A., Bowers, W.J., Virion-associated cofactor high-mobility group DNA-binding protein-1 facilitates transposition from the herpes simplex virus/Sleeping Beauty amplicon vector platform. Human Gene Therapy 21:11 (2010), 1615–1622.
35. de Souza, A.W., Westra, J., Limburg, P.C., Bijl, M., Kallenberg, C.G., HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis. Autoimmunity Reviews 11:12 (2012), 909–917, 10.1016/j.autrev.2012.03.007.
36. Degryse, B., Bonaldi, T., Scaffidi, P., Muller, S., Resnati, M., Sanvito, F., Bianchi, M.E., The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. The Journal of Cell Biology 152:6 (2001), 1197–1206.
37. Duguet, M., Soussi, T., Rossignol, J.M., Mechali, M., De Recondo, A.M., Stimulation of rat liver alpha- and beta-type DNA polymerases by an homologous DNA-unwinding protein. FEBS Letters 79:1 (1977), 160–164.
38. Dyson, M., Walker, J.M., Chromatin associated protease from calf thymus. International Journal of Peptide and Protein Research 24:3 (1984), 201–207.
39. El Mezayen, R., El Gazzar, M., Seeds, M.C., McCall, C.E., Dreskin, S.C., Nicolls, M.R., Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunology Letters 111:1 (2007), 36–44, 10.1016/j.imlet.2007.04.011.
40. Elenkov, I., Pelovsky, P., Ugrinova, I., Takahashi, M., Pasheva, E., The DNA binding and bending activities of truncated tail-less HMGB1 protein are differentially affected by Lys-2 and Lys-81 residues and their acetylation. International Journal of Biological Sciences 7:6 (2011), 691–699.
41. Ellerman, J.E., Brown, C.K., de Vera, M., Zeh, H.J., Billiar, T., Rubartelli, A., Lotze, M.T., Masquerader: High mobility group box-1 and cancer. Clinical Cancer Research 13:10 (2007), 2836–2848, 10.1158/1078-0432.CCR-06-1953.
42. Gaillard, C., Strauss, F., DNA loops and semicatenated DNA junctions. BMC Biochemistry, 1, 2000, 1, 10.1186/1471-2091-1-1.
43. Gao, Q., Ma, L.L., Gao, X., Yan, W., Williams, P., Yin, D.P., TLR4 mediates early graft failure after intraportal islet transplantation. American Journal of Transplantation 10:7 (2010), 1588–1596, 10.1111/j.1600-6143.2010.03151.x.
44. Gong, G., Yuan, L.B., Hu, L., Wu, W., Yin, L., Hou, J.L., Zhou, L.S., Glycyrrhizin attenuates rat ischemic spinal cord injury by suppressing inflammatory cytokines and HMGB1. Acta Pharmacologica Sinica 33:1 (2012), 11–18, 10.1038/aps.2011.151.
45. Goodwin, G.H., Sanders, C., Johns, E.W., A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. European Journal of Biochemistry 38:1 (1973), 14–19.
46. Grosschedl, R., Giese, K., Pagel, J., HMG domain proteins: Architectural elements in the assembly of nucleoprotein structures. Trends in Genetics 10:3 (1994), 94–100.
47. Guo, S., Bai, R., Liu, W., Zhao, A., Zhao, Z., Wang, Y., Wang, W., miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy. Tumour Biology 35:7 (2014), 7025–7034, 10.1007/s13277-014-1965-2.
48. Hagiwara, S., Iwasaka, H., Matsumoto, S., Hasegawa, A., Yasuda, N., Noguchi, T., In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models. Shock 33:3 (2010), 282–288, 10.1097/SHK.0b013e3181b0ef7b.
49. Hamada, N., Maeyama, T., Kawaguchi, T., Yoshimi, M., Fukumoto, J., Yamada, M., Nakanishi, Y., The role of high mobility group box1 in pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology 39:4 (2008), 440–447, 10.1165/rcmb.2007-0330OC.
50. He, M., Kubo, H., Morimoto, K., Fujino, N., Suzuki, T., Takahasi, T., Yamamoto, H., Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO Reports 12:4 (2011), 358–364, 10.1038/embor.2011.28.
51. He, Y., Zha, J., Wang, Y., Liu, W., Yang, X., Yu, P., Tissue damage-associated “danger signals” influence T-cell responses that promote the progression of preneoplasia to cancer. Cancer Research 73:2 (2013), 629–639, 10.1158/0008-5472.CAN-12-2704.
52. Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J.X., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. The Journal of Biological Chemistry 270:43 (1995), 25752–25761.
53. Huttunen, H.J., Fages, C., Rauvala, H., Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. The Journal of Biological Chemistry 274:28 (1999), 19919–19924.
54. Jantzen, H.M., Admon, A., Bell, S.P., Tjian, R., Nucleolar transcription factor hUBF contains a DNA-binding motif with homology to HMG proteins. Nature 344:6269 (1990), 830–836, 10.1038/344830a0.
55. Jayaraman, L., Moorthy, N.C., Murthy, K.G., Manley, J.L., Bustin, M., Prives, C., High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes & Development 12:4 (1998), 462–472.
56. Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Tang, D., HMGB1 in health and disease. Molecular Aspects of Medicine 40 (2014), 1–116, 10.1016/j.mam.2014.05.001.
57. Kang, R., Zhang, Q., Zeh, H.J. 3rd, Lotze, M.T., Tang, D., HMGB1 in cancer: Good, bad, or both?. Clinical Cancer Research 19:15 (2013), 4046–4057, 10.1158/1078-0432.CCR-13-0495.
58. Kim, K., Han, J.S., Kim, H.A., Lee, M., Expression, purification and characterization of TAT-high mobility group box-1A peptide as a carrier of nucleic acids. Biotechnology Letters 30:8 (2008), 1331–1337, 10.1007/s10529-008-9695-4.
59. Kokkola, R., Li, J., Sundberg, E., Aveberger, A.C., Palmblad, K., Yang, H., Harris, H.E., Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis and Rheumatism 48:7 (2003), 2052–2058, 10.1002/art.11161.
60. Kono, H., Rock, K.L., How dying cells alert the immune system to danger. Nature Reviews. Immunology 8:4 (2008), 279–289, 10.1038/nri2215.
61. Kostova, N., Zlateva, S., Ugrinova, I., Pasheva, E., The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Molecular and Cellular Biochemistry 337:1–2 (2010), 251–258, 10.1007/s11010-009-0305-0.
62. Koulis, C., de Haan, J.B., Allen, T.J., Novel pathways and therapies in experimental diabetic atherosclerosis. Expert Review of Cardiovascular Therapy 10:3 (2012), 323–335, 10.1586/erc.12.13.
63. Kuroiwa, Y., Takakusagi, Y., Kusayanagi, T., Kuramochi, K., Imai, T., Hirayama, T., Sugawara, F., Identification and characterization of the direct interaction between methotrexate (MTX) and high-mobility group box 1 (HMGB1) protein. PLoS One, 8(5), 2013, e63073, 10.1371/journal.pone.0063073.
64. Lamore, S.D., Cabello, C.M., Wondrak, G.T., HMGB1-directed drug discovery targeting cutaneous inflammatory dysregulation. Current Drug Metabolism 11:3 (2010), 250–265.
65. Lange, S.S., Reddy, M.C., Vasquez, K.M., Human HMGB1 directly facilitates interactions between nucleotide excision repair proteins on triplex-directed psoralen interstrand crosslinks. DNA Repair (Amst) 8:7 (2009), 865–872, 10.1016/j.dnarep.2009.04.001.
66. Lange, S.S., Vasquez, K.M., HMGB1: The jack-of-all-trades protein is a master DNA repair mechanic. Molecular Carcinogenesis 48:7 (2009), 571–580, 10.1002/mc.20544.
67. Li, W., Ashok, M., Li, J., Yang, H., Sama, A.E., Wang, H., A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One, 2(11), 2007, e1153, 10.1371/journal.pone.0001153.
68. Li, H., Huang, W., Luo, R., The microRNA-325 inhibits hepatocellular carcinoma progression by targeting high mobility group box 1. Diagnostic Pathology, 10, 2015, 117, 10.1186/s13000-015-0323-z.
69. Li, J., Kokkola, R., Tabibzadeh, S., Yang, R., Ochani, M., Qiang, X., Yang, H., Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Molecular Medicine 9:1–2 (2003), 37–45.
70. Li, D., Lei, C., Zhang, S., Zhang, S., Liu, M., Wu, B., Blockade of high mobility group box-1 signaling via the receptor for advanced glycation end-products ameliorates inflammatory damage after acute intracerebral hemorrhage. Neuroscience Letters 609 (2015), 109–119, 10.1016/j.neulet.2015.10.035.
71. Li, M., Sun, L., Luo, Y., Xie, C., Pang, Y., Li, Y., High-mobility group box 1 released from astrocytes promotes the proliferation of cultured neural stem/progenitor cells. International Journal of Molecular Medicine 34:3 (2014), 705–714, 10.3892/ijmm.2014.1820.
72. Li, X., Wang, S., Chen, Y., Liu, G., Yang, X., miR-22 targets the 3′ UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy. Tumour Biology 35:6 (2014), 6021–6028, 10.1007/s13277-014-1797-0.
73. Li, M.L., Wang, X.F., Tan, Z.J., Dong, P., Gu, J., Lu, J.H., Liu, Y.B., Ethyl pyruvate administration suppresses growth and invasion of gallbladder cancer cells via downregulation of HMGB1-RAGE axis. International Journal of Immunopathology and Pharmacology 25:4 (2012), 955–965.
74. Lin, Q., Yang, X.P., Fang, D., Ren, X., Zhou, H., Fang, J., Su, S.B., High-mobility group box-1 mediates toll-like receptor 4-dependent angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 31:5 (2011), 1024–1032, 10.1161/ATVBAHA.111.224048.
75. Liu, K., Huang, J., Xie, M., Yu, Y., Zhu, S., Kang, R., Duan, X., MIR34A regulates autophagy and apoptosis by targeting HMGB1 in the retinoblastoma cell. Autophagy 10:3 (2014), 442–452, 10.4161/auto.27418.
76. Luo, Y., Chihara, Y., Fujimoto, K., Sasahira, T., Kuwada, M., Fujiwara, R., Kuniyasu, H., High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. European Journal of Cancer 49:3 (2013), 741–751, 10.1016/j.ejca.2012.09.016.
77. Maeda, T., Ozaki, M., Kobayashi, Y., Kiguchi, N., Kishioka, S., HMGB1 as a potential therapeutic target for neuropathic pain. Journal of Pharmacological Sciences 123:4 (2013), 301–305.
78. Magna, M., Pisetsky, D.S., The role of cell death in the pathogenesis of SLE: Is pyroptosis the missing link?. Scandinavian Journal of Immunology 82:3 (2015), 218–224, 10.1111/sji.12335.
79. Manigrasso, M.B., Juranek, J., Ramasamy, R., Schmidt, A.M., Unlocking the biology of RAGE in diabetic microvascular complications. Trends in Endocrinology and Metabolism 25:1 (2014), 15–22, 10.1016/j.tem.2013.08.002.
80. Mardente, S., Mari, E., Consorti, F., Di Gioia, C., Negri, R., Etna, M., Antonaci, A., HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells. Oncology Reports 28:6 (2012), 2285–2289, 10.3892/or.2012.2058.
81. Mardente, S., Mari, E., Massimi, I., Fico, F., Faggioni, A., Pulcinelli, F., Zicari, A., HMGB1-induced cross talk between PTEN and miRs 221/222 in thyroid cancer. BioMed Research International, 2015, 2015, 512027, 10.1155/2015/512027.
82. Maroso, M., Balosso, S., Ravizza, T., Liu, J., Aronica, E., Iyer, A.M., Vezzani, A., Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nature Medicine 16:4 (2010), 413–419, 10.1038/nm.2127.
83. Matzinger, P., Tolerance, danger, and the extended family. Annual Review of Immunology 12 (1994), 991–1045, 10.1146/annurev.iy.12.040194.005015.
84. Mazarati, A., Maroso, M., Iori, V., Vezzani, A., Carli, M., High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and receptor for advanced glycation end products. Experimental Neurology 232:2 (2011), 143–148, 10.1016/j.expneurol.2011.08.012.
85. Min, H.J., Ko, E.A., Wu, J., Kim, E.S., Kwon, M.K., Kwak, M.S., Shin, J.S., Chaperone-like activity of high-mobility group box 1 protein and its role in reducing the formation of polyglutamine aggregates. Journal of Immunology 190:4 (2013), 1797–1806, 10.4049/jimmunol.1202472.
86. Mitkova, E., Ugrinova, I., Pashev, I.G., Pasheva, E.A., The inhibitory effect of HMGB-1 protein on the repair of cisplatin-damaged DNA is accomplished through the acidic domain. Biochemistry 44:15 (2005), 5893–5898, 10.1021/bi047712c.
87. Mitsouras, K., Wong, B., Arayata, C., Johnson, R.C., Carey, M., The DNA architectural protein HMGB1 displays two distinct modes of action that promote enhanceosome assembly. Molecular and Cellular Biology 22:12 (2002), 4390–4401.
88. Mittal, D., Saccheri, F., Venereau, E., Pusterla, T., Bianchi, M.E., Rescigno, M., TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. The EMBO Journal 29:13 (2010), 2242–2252, 10.1038/emboj.2010.94.
89. Mollica, L., De Marchis, F., Spitaleri, A., Dallacosta, C., Pennacchini, D., Zamai, M., Bianchi, M.E., Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chemistry & Biology 14:4 (2007), 431–441, 10.1016/j.chembiol.2007.03.007.
90. Musumeci, D., Bucci, E.M., Roviello, G.N., Sapio, R., Valente, M., Moccia, M., Pedone, C., DNA-based strategies for blocking HMGB1 cytokine activity: Design, synthesis and preliminary in vitro/in vivo assays of DNA and DNA-like duplexes. Molecular BioSystems 7:5 (2011), 1742–1752, 10.1039/c1mb05009e.
91. Musumeci, D., Roviello, G.N., Moccia, M., Pedone, C., Bucci, E.M., Sapio, R., Fumero, S., Bent oligonucleotide duplexes as HMGB1 inhibitors: A comparative study. Nucleosides, Nucleotides & Nucleic Acids 26:10–12 (2007), 1447–1450, 10.1080/15257770701542330.
92. Musumeci, D., Roviello, G.N., Montesarchio, D., An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacology & Therapeutics 141:3 (2014), 347–357, 10.1016/j.pharmthera.2013.11.001.
93. Ogiku, M., Kono, H., Hara, M., Tsuchiya, M., Fujii, H., Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by Kupffer cells after ischemia-reperfusion in rats. The Journal of Pharmacology and Experimental Therapeutics 339:1 (2011), 93–98, 10.1124/jpet.111.182592.
94. Ohmori, H., Luo, Y., Fujii, K., Sasahira, T., Shimomoto, T., Denda, A., Kuniyasu, H., Dietary linoleic acid and glucose enhances azoxymethane-induced colon cancer and metastases via the expression of high-mobility group box 1. Pathobiology 77:4 (2010), 210–217, 10.1159/000296305.
95. Park, S., Yoon, S.J., Tae, H.J., Shim, C.Y., RAGE and cardiovascular disease. Frontiers in Bioscience (Landmark edition) 16 (2011), 486–497.
96. Pasheva, E.A., Pashev, I.G., Favre, A., Preferential binding of high mobility group 1 protein to UV-damaged DNA. Role of the COOH-terminal domain. The Journal of Biological Chemistry 273:38 (1998), 24730–24736.
97. Pasheva, E., Sarov, M., Bidjekov, K., Ugrinova, I., Sarg, B., Lindner, H., Pashev, I.G., In vitro acetylation of HMGB-1 and -2 proteins by CBP: The role of the acidic tail. Biochemistry 43:10 (2004), 2935–2940, 10.1021/bi035615y.
98. Pasheva, E.A., Ugrinova, I., Spassovska, N.C., Pashev, I.G., The binding affinity of HMG1 protein to DNA modified by cis-platin and its analogs correlates with their antitumor activity. The International Journal of Biochemistry & Cell Biology 34:1 (2002), 87–92.
99. Patrick, S.M., Turchi, J.J., Replication protein A (RPA) binding to duplex cisplatin-damaged DNA is mediated through the generation of single-stranded DNA. The Journal of Biological Chemistry 274:21 (1999), 14972–14978.
100. Paull, T.T., Haykinson, M.J., Johnson, R.C., The nonspecific DNA-binding and -bending proteins HMG1 and HMG2 promote the assembly of complex nucleoprotein structures. Genes & Development 7:8 (1993), 1521–1534.
101. Pedrazzi, M., Averna, M., Sparatore, B., Patrone, M., Salamino, F., Marcoli, M., Melloni, E., Potentiation of NMDA receptor-dependent cell responses by extracellular high mobility group box 1 protein. PLoS One, 7(8), 2012, e44518, 10.1371/journal.pone.0044518.
102. Peterson, E.B., Mastrangelo, M.A., Federoff, H.J., Bowers, W.J., Neuronal specificity of HSV/sleeping beauty amplicon transduction in utero is driven primarily by tropism and cell type composition. Molecular Therapy 15:10 (2007), 1848–1855.
103. Phair, R.D., Scaffidi, P., Elbi, C., Vecerova, J., Dey, A., Ozato, K., Misteli, T., Global nature of dynamic protein-chromatin interactions in vivo: Three-dimensional genome scanning and dynamic interaction networks of chromatin proteins. Molecular and Cellular Biology 24:14 (2004), 6393–6402, 10.1128/MCB.24.14.6393-6402.2004.
104. Pil, P.M., Chow, C.S., Lippard, S.J., High-mobility-group 1 protein mediates DNA bending as determined by ring closures. Proceedings of the National Academy of Sciences of the United States of America 90:20 (1993), 9465–9469.
105. Pil, P.M., Lippard, S.J., Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256:5054 (1992), 234–237.
106. Pisetsky, D.S., Erlandsson-Harris, H., Andersson, U., High-mobility group box protein 1 (HMGB1): An alarmin mediating the pathogenesis of rheumatic disease. Arthritis Research & Therapy, 10(3), 2008, 209, 10.1186/ar2440.
107. Qin, Y., Chen, Y., Wang, W., Wang, Z., Tang, G., Zhang, P., Shen, Q., HMGB1-LPS complex promotes transformation of osteoarthritis synovial fibroblasts to a rheumatoid arthritis synovial fibroblast-like phenotype. Cell Death & Disease, 5, 2014, e1077, 10.1038/cddis.2014.48.
108. Qiu, Y., Yang, J., Wang, W., Zhao, W., Peng, F., Xiang, Y., Feng, J., HMGB1-promoted and TLR2/4-dependent NK cell maturation and activation take part in rotavirus-induced murine biliary atresia. PLoS Pathogens, 10(3), 2014, e1004011, 10.1371/journal.ppat.1004011.
109. Raman, K.G., Sappington, P.L., Yang, R., Levy, R.M., Prince, J.M., Liu, S., Fink, M.P., The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock. American Journal of Physiology. Gastrointestinal and Liver Physiology 291:4 (2006), G556–G565, 10.1152/ajpgi.00055.2006.
110. Ran, X., Yang, J., Liu, C., Zhou, P., Xiao, L., Zhang, K., MiR-218 inhibits HMGB1-mediated autophagy in endometrial carcinoma cells during chemotherapy. International Journal of Clinical and Experimental Pathology 8:6 (2015), 6617–6626.
111. Raucci, A., Cugusi, S., Antonelli, A., Barabino, S.M., Monti, L., Bierhaus, A., Bianchi, M.E., A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). The FASEB Journal 22:10 (2008), 3716–3727, 10.1096/fj.08-109033.
112. Rauvala, H., Pihlaskari, R., Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. The Journal of Biological Chemistry 262:34 (1987), 16625–16635.
113. Reddy, M.C., Christensen, J., Vasquez, K.M., Interplay between human high mobility group protein 1 and replication protein A on psoralen-cross-linked DNA. Biochemistry 44:11 (2005), 4188–4195, 10.1021/bi047902n.
114. Reed, E., Ozols, R.F., Tarone, R., Yuspa, S.H., Poirier, M.C., Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proceedings of the National Academy of Sciences of the United States of America 84:14 (1987), 5024–5028.
115. Romani, M., Rodman, T.C., Vidali, G., Bustin, M., Serological analysis of species specificity in the high mobility group chromosomal proteins. The Journal of Biological Chemistry 254:8 (1979), 2918–2922.
116. Sakamoto, R., Okano, M., Takena, H., Ohtsuki, K., Inhibitory effect of glycyrrhizin on the phosphorylation and DNA-binding abilities of high mobility group proteins 1 and 2 in vitro. Biological & Pharmaceutical Bulletin 24:8 (2001), 906–911.
117. Sanchez-Giraldo, R., Acosta-Reyes, F.J., Malarkey, C.S., Saperas, N., Churchill, M.E., Campos, J.L., Two high-mobility group box domains act together to underwind and kink DNA. Acta Crystallographica. Section D, Biological Crystallography 71:Pt. 7 (2015), 1423–1432, 10.1107/S1399004715007452.
118. Scaffidi, P., Misteli, T., Bianchi, M.E., Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:6894 (2002), 191–195, 10.1038/nature00858.
119. Schaper, F., Westra, J., Bijl, M., Recent developments in the role of high-mobility group box 1 in systemic lupus erythematosus. Molecular Medicine 20 (2014), 72–79, 10.2119/molmed.2014.00019.
120. Schierbeck, H., Lundback, P., Palmblad, K., Klevenvall, L., Erlandsson-Harris, H., Andersson, U., Ottosson, L., Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Molecular Medicine 17:9–10 (2011), 1039–1044, 10.2119/molmed.2010.00264.
121. Schiraldi, M., Raucci, A., Munoz, L.M., Livoti, E., Celona, B., Venereau, E., Uguccioni, M., HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. The Journal of Experimental Medicine 209:3 (2012), 551–563, 10.1084/jem.20111739.
122. Sims, G.P., Rowe, D.C., Rietdijk, S.T., Herbst, R., Coyle, A.J., HMGB1 and RAGE in inflammation and cancer. Annual Review of Immunology 28 (2010), 367–388, 10.1146/annurev.immunol.021908.132603.
123. Singh, J., Dixon, G.H., High mobility group proteins 1 and 2 function as general class II transcription factors. Biochemistry 29:26 (1990), 6295–6302.
124. Sitia, G., Iannacone, M., Muller, S., Bianchi, M.E., Guidotti, L.G., Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. Journal of Leukocyte Biology 81:1 (2007), 100–107, 10.1189/jlb.0306173.
125. Siu, Y.S., Li, L., Leung, M.F., Lee, K.L., Li, P., Polyethylenimine-based amphiphilic core-shell nanoparticles: Study of gene delivery and intracellular trafficking. Biointerphases, 7(1–4), 2012, 16, 10.1007/s13758-011-0016-4.
126. Smolarczyk, R., Cichon, T., Matuszczak, S., Mitrus, I., Lesiak, M., Kobusinska, M., Szala, S., The role of Glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy. Archivum Immunologiae et Therapiae Experimentalis 60:5 (2012), 391–399, 10.1007/s00005-012-0183-0.
127. Song, J.X., Lu, J.H., Liu, L.F., Chen, L.L., Durairajan, S.S., Yue, Z., Li, M., HMGB1 is involved in autophagy inhibition caused by SNCA/alpha-synuclein overexpression: A process modulated by the natural autophagy inducer corynoxine B. Autophagy 10:1 (2014), 144–154, 10.4161/auto.26751.
128. Sterner, R., Vidali, G., Allfrey, V.G., Studies of acetylation and deacetylation in high mobility group proteins. Identification of the sites of acetylation in HMG-1. The Journal of Biological Chemistry 254:22 (1979), 11577–11583.
129. Stott, K., Watson, M., Howe, F.S., Grossmann, J.G., Thomas, J.O., Tail-mediated collapse of HMGB1 is dynamic and occurs via differential binding of the acidic tail to the A and B domains. Journal of Molecular Biology 403:5 (2010), 706–722, 10.1016/j.jmb.2010.07.045.
130. Stros, M., Stokrova, J., Thomas, J.O., DNA looping by the HMG-box domains of HMG1 and modulation of DNA binding by the acidic C-terminal domain. Nucleic Acids Research 22:6 (1994), 1044–1051.
131. Su, S., Wu, J., Gong, T., He, K., Feng, C., Zhang, M., Xia, X., Inhibition of high mobility group box 1-toll-like receptor-4 signaling by glycyrrhizin contributes to the attenuation of cold ischemic injury of liver in a rat model. Transplantation Proceedings 48:1 (2016), 191–198, 10.1016/j.transproceed.2015.12.014.
132. Susa, Y., Masuda, Y., Imaizumi, H., Namiki, A., Neutralization of receptor for advanced glycation end-products and high mobility group box-1 attenuates septic diaphragm dysfunction in rats with peritonitis. Critical Care Medicine 37:9 (2009), 2619–2624, 10.1097/CCM.0b013e3181a930f7.
133. Taguchi, A., Blood, D.C., del Toro, G., Canet, A., Lee, D.C., Qu, W., Schmidt, A.M., Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405:6784 (2000), 354–360, 10.1038/35012626.
134. Tang, D., Kang, R., Xiao, W., Zhang, H., Lotze, M.T., Wang, H., Xiao, X., Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. American Journal of Respiratory Cell and Molecular Biology 41:6 (2009), 651–660, 10.1165/rcmb.2008-0119OC.
135. Tang, D., Kang, R., Zeh, H.J. 3rd, Lotze, M.T., High-mobility group box 1 and cancer. Biochimica et Biophysica Acta 1799:1–2 (2010), 131–140, 10.1016/j.bbagrm.2009.11.014.
136. Tang, Y., Lv, B., Wang, H., Xiao, X., Zuo, X., PACAP inhibit the release and cytokine activity of HMGB1 and improve the survival during lethal endotoxemia. International Immunopharmacology 8:12 (2008), 1646–1651, 10.1016/j.intimp.2008.07.014.
137. Terheggen, P.M., Emondt, J.Y., Floot, B.G., Dijkman, R., Schrier, P.I., den Engelse, L., Begg, A.C., Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Research 50:12 (1990), 3556–3561.
138. Therrien, J.P., Drouin, R., Baril, C., Drobetsky, E.A., Human cells compromised for p53 function exhibit defective global and transcription-coupled nucleotide excision repair, whereas cells compromised for pRb function are defective only in global repair. Proceedings of the National Academy of Sciences of the United States of America 96:26 (1999), 15038–15043.
139. Topalova, D., Ugrinova, I., Pashev, I.G., Pasheva, E.A., HMGB1 protein inhibits DNA replication in vitro: A role of the acetylation and the acidic tail. The International Journal of Biochemistry & Cell Biology 40:8 (2008), 1536–1542, 10.1016/j.biocel.2007.11.014.
140. Tsung, A., Hoffman, R.A., Izuishi, K., Critchlow, N.D., Nakao, A., Chan, M.H., Billiar, T.R., Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. Journal of Immunology 175:11 (2005), 7661–7668.
141. Tsung, A., Sahai, R., Tanaka, H., Nakao, A., Fink, M.P., Lotze, M.T., Billiar, T.R., The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. The Journal of Experimental Medicine 201:7 (2005), 1135–1143, 10.1084/jem.20042614.
142. Ueda, T., Chou, H., Kawase, T., Shirakawa, H., Yoshida, M., Acidic C-tail of HMGB1 is required for its target binding to nucleosome linker DNA and transcription stimulation. Biochemistry 43:30 (2004), 9901–9908, 10.1021/bi035975l.
143. Ugrinova, I., Mitkova, E., Moskalenko, C., Pashev, I., Pasheva, E., DNA bending versus DNA end joining activity of HMGB1 protein is modulated in vitro by acetylation. Biochemistry 46:8 (2007), 2111–2117, 10.1021/bi0614479.
144. Ugrinova, I., Pashev, I.G., Pasheva, E.A., Nucleosome binding properties and Co-remodeling activities of native and in vivo acetylated HMGB-1 and HMGB-2 proteins. Biochemistry 48:27 (2009), 6502–6507, 10.1021/bi9004304.
145. Ugrinova, I., Pasheva, E.A., Armengaud, J., Pashev, I.G., In vivo acetylation of HMG1 protein enhances its binding affinity to distorted DNA structures. Biochemistry 40:48 (2001), 14655–14660.
146. Ugrinova, I., Zlateva, S., Pashev, I.G., Pasheva, E.A., Native HMGB1 protein inhibits repair of cisplatin-damaged nucleosomes in vitro. The International Journal of Biochemistry & Cell Biology 41:7 (2009), 1556–1562, 10.1016/j.biocel.2009.01.010.
147. Ulloa, L., Messmer, D., High-mobility group box 1 (HMGB1) protein: Friend and foe. Cytokine & Growth Factor Reviews 17:3 (2006), 189–201, 10.1016/j.cytogfr.2006.01.003.
148. Ulloa, L., Ochani, M., Yang, H., Tanovic, M., Halperin, D., Yang, R., Tracey, K.J., Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proceedings of the National Academy of Sciences of the United States of America 99:19 (2002), 12351–12356, 10.1073/pnas.192222999.
149. van Beijnum, J.R., Nowak-Sliwinska, P., van den Boezem, E., Hautvast, P., Buurman, W.A., Griffioen, A.W., Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 32:3 (2013), 363–374, 10.1038/onc.2012.49.
150. Venereau, E., Casalgrandi, M., Schiraldi, M., Antoine, D.J., Cattaneo, A., De Marchis, F., Bianchi, M.E., Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. The Journal of Experimental Medicine 209:9 (2012), 1519–1528, 10.1084/jem.20120189.
151. Venereau, E., De Leo, F., Mezzapelle, R., Careccia, G., Musco, G., Bianchi, M.E., HMGB1 as biomarker and drug target. Pharmacological Research 111 (2016), 534–544, 10.1016/j.phrs.2016.06.031.
152. Wan, W., Cao, L., Khanabdali, R., Kalionis, B., Tai, X., Xia, S., The emerging role of HMGB1 in neuropathic pain: A potential therapeutic target for neuroinflammation. Journal of Immunology Research, 2016, 2016, 6430423, 10.1155/2016/6430423.
153. Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J.M., Ombrellino, M., Che, J., Tracey, K.J., HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:5425 (1999), 248–251.
154. Wang, X., Guo, Y., Wang, C., Yu, H., Yu, X., Yu, H., MicroRNA-142-3p inhibits chondrocyte apoptosis and inflammation in osteoarthritis by targeting HMGB1. Inflammation 39:5 (2016), 1718–1728, 10.1007/s10753-016-0406-3.
155. Wang, X., Sun, R., Wei, H., Tian, Z., High-mobility group box 1 (HMGB1)-Toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: Interaction of gammadelta T cells with macrophages. Hepatology 57:1 (2013), 373–384, 10.1002/hep.25982.
156. Wang, H., Ward, M.F., Sama, A.E., Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 32:4 (2009), 348–357, 10.1097/SHK.0b013e3181a551bd.
157. Weir, H.M., Kraulis, P.J., Hill, C.S., Raine, A.R., Laue, E.D., Thomas, J.O., Structure of the HMG box motif in the B-domain of HMG1. The EMBO Journal 12:4 (1993), 1311–1319.
158. Wu, L., Cai, C., Wang, X., Liu, M., Li, X., Tang, H., MicroRNA-142-3p, a new regulator of RAC1, suppresses the migration and invasion of hepatocellular carcinoma cells. FEBS Letters 585:9 (2011), 1322–1330, 10.1016/j.febslet.2011.03.067.
159. Wu, J., Li, J., Salcedo, R., Mivechi, N.F., Trinchieri, G., Horuzsko, A., The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Research 72:16 (2012), 3977–3986, 10.1158/0008-5472.CAN-12-0938.
160. Xiao, P., Liu, W.L., MiR-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma. International Journal of Clinical and Experimental Pathology 8:9 (2015), 10800–10807.
161. Xie, J., Hu, X., Yi, C., Hu, G., Zhou, X., Jiang, H., MicroRNA451 protects against cardiomyocyte anoxia/reoxygenation injury by inhibiting high mobility group box 1 expression. Molecular Medicine Reports 13:6 (2016), 5335–5341, 10.3892/mmr.2016.5192.
162. Yanai, H., Ban, T., Wang, Z., Choi, M.K., Kawamura, T., Negishi, H., Taniguchi, T., HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462:7269 (2009), 99–103, 10.1038/nature08512.
163. Yang, H., Antoine, D.J., Andersson, U., Tracey, K.J., The many faces of HMGB1: Molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. Journal of Leukocyte Biology 93:6 (2013), 865–873, 10.1189/jlb.1212662.
164. Yang, Z., Deng, Y., Su, D., Tian, J., Gao, Y., He, Z., Wang, X., TLR4 as receptor for HMGB1-mediated acute lung injury after liver ischemia/reperfusion injury. Laboratory Investigation 93:7 (2013), 792–800, 10.1038/labinvest.2013.66.
165. Yang, H., Hreggvidsdottir, H.S., Palmblad, K., Wang, H., Ochani, M., Li, J., Tracey, K.J., A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proceedings of the National Academy of Sciences of the United States of America 107:26 (2010), 11942–11947, 10.1073/pnas.1003893107.
166. Yang, H., Lundback, P., Ottosson, L., Erlandsson-Harris, H., Venereau, E., Bianchi, M.E., Antoine, D.J., Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Molecular Medicine 18 (2012), 250–259, 10.2119/molmed.2011.00389.
167. Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H.E., Tracey, K.J., Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proceedings of the National Academy of Sciences of the United States of America 101:1 (2004), 296–301, 10.1073/pnas.2434651100.
168. Yang, H., Wang, H., Chavan, S.S., Andersson, U., High mobility group box protein 1 (HMGB1): The prototypical endogenous danger molecule. Molecular Medicine 21:Suppl. 1 (2015), S6–S12, 10.2119/molmed.2015.00087.
169. Yang, H., Wang, H., Ju, Z., Ragab, A.A., Lundback, P., Long, W., Al-Abed, Y., MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. The Journal of Experimental Medicine 212:1 (2015), 5–14, 10.1084/jem.20141318.
170. Yang, H., Wang, H., Levine, Y.A., Gunasekaran, M.K., Wang, Y., Addorisio, M., Tracey, K.J., Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes. JCI Insight, 1(7), 2016, e85375, 10.1172/jci.insight.85375.
171. Yao, S., Zhao, T., Jin, H., Expression of MicroRNA-325-3p and its potential functions by targeting HMGB1 in non-small cell lung cancer. Biomedicine & Pharmacotherapy 70 (2015), 72–79, 10.1016/j.biopha.2015.01.013.
172. Yi, W.J., Yang, J., Li, C., Wang, H.Y., Liu, C.W., Tao, L., Zhang, X.Z., Enhanced nuclear import and transfection efficiency of TAT peptide-based gene delivery systems modified by additional nuclear localization signals. Bioconjugate Chemistry 23:1 (2012), 125–134, 10.1021/bc2005472.
173. Yu, Y., Tang, D., Kang, R., Oxidative stress-mediated HMGB1 biology. Frontiers in Physiology, 6, 2015, 93, 10.3389/fphys.2015.00093.
174. Yu, M., Wang, H., Ding, A., Golenbock, D.T., Latz, E., Czura, C.J., Yang, H., HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26:2 (2006), 174–179, 10.1097/01.shk.0000225404.51320.82.
175. Yusein-Myashkova, S., Stoykov, I., Gospodinov, A., Ugrinova, I., Pasheva, E., The repair capacity of lung cancer cell lines A549 and H1299 depends on HMGB1 expression level and the p53 status. Journal of Biochemistry 160:1 (2016), 37–47, 10.1093/jb/mvw012.
176. Zamble, D.B., Lippard, S.J., Cisplatin and DNA repair in cancer chemotherapy. Trends in Biochemical Sciences 20:10 (1995), 435–439.
177. Zhai, C.L., Zhang, M.Q., Zhang, Y., Xu, H.X., Wang, J.M., An, G.P., Li, L., Glycyrrhizin protects rat heart against ischemia-reperfusion injury through blockade of HMGB1-dependent phospho-JNK/Bax pathway. Acta Pharmacologica Sinica 33:12 (2012), 1477–1487, 10.1038/aps.2012.112.
178. Zhang, L., Bukulin, M., Kojro, E., Roth, A., Metz, V.V., Fahrenholz, F., Postina, R., Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. The Journal of Biological Chemistry 283:51 (2008), 35507–35516, 10.1074/jbc.M806948200.
179. Zhang, C., Ge, S., Hu, C., Yang, N., Zhang, J., MiRNA-218, a new regulator of HMGB1, suppresses cell migration and invasion in non-small cell lung cancer. Acta Biochimica et Biophysica Sinica Shanghai 45:12 (2013), 1055–1061, 10.1093/abbs/gmt109.
180. Zhou, W., Wang, J., Li, Z., Li, J., Sang, M., MicroRNA-2055b inhibits HMGB1 expression in LPS-induced sepsis. International Journal of Molecular Medicine 38:1 (2016), 312–318, 10.3892/ijmm.2016.2613.
181. Zong, H., Madden, A., Ward, M., Mooney, M.H., Elliott, C.T., Stitt, A.W., Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. The Journal of Biological Chemistry 285:30 (2010), 23137–23146, 10.1074/jbc.M110.133827.